Teva Pharmaceutical Industries Ltd (TEVA)
$10.38
0.17 (1.67%)
TEVA Stock Quote Delayed 15 Minutes
Previous Close
$10.25
Market Cap
10.57B
PE Ratio
-0.66
EPS
-15.8
Volume (Avg. Vol.)
228,099
Day's Range
10.21 - 10.21
52-Week Range
6.07 - 20.21
Dividend & Yield
0.07 (0.69%)
TEVA Stock Predictions, Articles, and Teva Pharmaceutical Industries Ltd News
Why Teva Stock Could Be the Next General Electric Stock
Teva can handle its debt and deal with its liability from the opioid tragedy. And Teva stock has multiple, positive catalysts.
Why Teva Investors Should Keep Their Hands on the Pause Button
Suffering from many missteps, generics drugmaker Teva is still struggling to heal. Here's what to expect from TEVA stock in 2020.
Buffett Owns Teva Stock, But Should You?
Teva stock has been a long-term loser, but there are signs that things are starting to turn around. Should investors consider it in 2020?
TEVA Stock Isn’t a Cure For Anything That Ails Investors
While Schulz's cost-cutting has reduced Teva's debt by more than $8 billion, more needs to be done to bolster the company's balance sheet.
Scandal-Ridden Teva Pharmaceutical Is Fishing for a Bottom
Teva's debt restructuring gives it breathing room through 2021, assuming its legal woes don't get worse. Buy Teva stock at your own risk.
The Diagnosis for Teva Stock Still Looks Grim
Lately, Teva stock has had a nice rally, but this may prove temporary. The fact is that the company faces much uncertainty with the litigation.
Stay on the Sidelines as the Future Looks Potentially Bleak for Teva Stock
With shares rebounded, now may not be the time to enter Teva stock. Wait to see how upcoming opioid trials play out. If shares pull back to prior price levels, a buying opportunity may emerge. But for now, the risks do not match up with potential upside.
Debt, Not Regulation, Is the Biggest Problem for Teva Stock
Teva stock has rallied from its lows on optimism toward legal settlements. But the balance sheet of TEVA remains an enormous risk.
Embattled TEVA Has Made Headlines for All of the Wrong Reasons
Teva Pharmaceuticals is under the glare of legal and regulatory scrutiny. However, TEVA will eventually find its way because frankly, it has to.
Teva Pharmaceuticals May Be a Speculator’s Dream Stock
For risk-averse investors, TEVA stock has many questions that make it a rough pick. But for the hardened speculator, it might be worth a shot.
Teva Stock Is Nothing but Trouble after Legal Issues
TEVA stock has earned its reputation - and I mean that in the worst possible way.
Teva Pharmaceuticals Stock Is Safe With Settlement Talks Underway
Despite the rally, Teva stock is inexpensive. The company is working on paying off its debt and building a strong generics portfolio.
4 Top Stock Trades for Wednesday: DIS, PANW, BURL, TEVA
Palo Alto Networks, Burlington Stores, Teva and Disney are our top stock trades to watch going into Wednesday.
Rebounding Teva Stock Could Climb Higher, But Risks Remain
The TEVA stock price has rebounded on a potential opioid settlement. But consider the company's other risks before buying Teva.
Why the Teva Stock Rebound May Be Real
TEVA stock is up 40% over the past month, and this may be just the beginning of a multi-year turnaround in the pharma giant.
With a Deal in Hand, Teva Stock Can Chart a Difficult Comeback
Teva stock fell sharply this year in large part thanks to the opioid crisis, but with a last-minute deal, shares look more interesting now.
Navellier Ratings
Powered by Portfolio GraderTotal Grade
F
